<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00283283</url>
  </required_header>
  <id_info>
    <org_study_id>A-13205</org_study_id>
    <nct_id>NCT00283283</nct_id>
  </id_info>
  <brief_title>Comparison of Full-dose Flu Vaccine to Half-dose Flu Vaccine</brief_title>
  <official_title>Clinical Study to Compare the Immune Response of Half Dose Trivalent Inactivated Influenza Vaccine (TIV) to Full Dose</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>U.S. Army Medical Research and Development Command</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Walter Reed Army Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>United States Army Medical Materiel Development Activity</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centers for Disease Control and Prevention</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Uniformed Services University of the Health Sciences</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Walter Reed Army Institute of Research (WRAIR)</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>U.S. Air Force Office of the Surgeon General</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>U.S. Army Medical Research and Development Command</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study compared full-dose Flu vaccine to half-dose Flu-vaccine during the 2004-2005 flu
      season.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a Phase II prospective, single-blind to dose, randomized study that compared the
      immunogenicity of subjects receiving half-dose Fluzone® compared to full-dose Fluzone®,
      2004-2005 formulation. 1440 healthy subjects, ages 18-64 years old and not currently
      indicated for influenza vaccination under the interim ACIP guidelines, were divided into 8
      strata based on age, gender, and previous exposure to influenza vaccine, and randomized to
      receive either half-dose (0.25mL) Fluzone® or full-dose (0.5mL) Fluzone® by intramuscular
      injection into the deltoid muscle.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2004</start_date>
  <completion_date type="Actual">May 2006</completion_date>
  <primary_completion_date type="Actual">November 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immune Response: Age 18-49</measure>
    <time_frame>21 days post-vaccincation</time_frame>
    <description>Immune response as measured by viral strain specific hemaggluttination inhibition (HAI) antibody levels for subjects ages 18-49</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immune Response: Age 50-64</measure>
    <time_frame>21 days post-vaccincation</time_frame>
    <description>Immune response as measured by viral strain specific hemaggluttination inhibition (HAI) antibody levels for subjects ages 50-64</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Medical Events: Unsolicited Adverse Events</measure>
    <time_frame>3 - 6 months following vaccination</time_frame>
    <description>Assessed through following subjects' recording of oral body temperature, completion of a 21-day symptom diary; subjects' completion of longer-term follow-up surveys to track respiratory symptoms; and a review of the Defense Medical Surveillance System (DMSS) hospitalization and outpatient medical visits database in order to track ICD-9 codes relevant to flu-like illness.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Race/Ethnicity Baseline Measure</measure>
    <time_frame>Enrollment Day</time_frame>
    <description>Race/ethnicity data was only collected by age and cannot be separated out by dose as per the other Baseline Measures</description>
  </other_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">1316</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Male, Age 18 -49, Full Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5ml, 15µg Fluzone® (Aventis Pasteur inactivated influenza vaccine) hemagglutinin antigen per strain</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Male, Age 50 -64, Half Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.25ml, 7.5µg Fluzone® (Aventis Pasteur inactivated influenza vaccine) hemagglutinia per strain</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Female, Age 18 - 49, Full Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5ml, 15µg Fluzone® (Aventis Pasteur inactivated influenza vaccine) hemagglutinin antigen per strain</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Female, Age 18 - 49, Half Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.25ml, 7.5µg Fluzone® (Aventis Pasteur inactivated influenza vaccine) hemagglutinia per strain</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Male, Age 18 - 49, Half Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.25ml, 7.5µg Fluzone® (Aventis Pasteur inactivated influenza vaccine) hemagglutinia per strain</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Male, Age 50 -64, Full Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5ml, 15µg Fluzone® (Aventis Pasteur inactivated influenza vaccine) hemagglutinin antigen per strain</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Female, Age 50 -64, Full Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5ml, 15µg Fluzone® (Aventis Pasteur inactivated influenza vaccine) hemagglutinin antigen per strain</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Female, Age 50 -64, Half Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.25ml, 7.5µg Fluzone® (Aventis Pasteur inactivated influenza vaccine) hemagglutinin antigen per strain</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fluzone® (Aventis Pasteur inactivated influenza vaccine)</intervention_name>
    <description>A/H1N1, A/New Caledonia/20/99; A/H3N2, A/Fujian/411/2002; B, B/Shanghai/361/2002</description>
    <arm_group_label>Female, Age 18 - 49, Full Dose</arm_group_label>
    <arm_group_label>Female, Age 18 - 49, Half Dose</arm_group_label>
    <arm_group_label>Female, Age 50 -64, Full Dose</arm_group_label>
    <arm_group_label>Female, Age 50 -64, Half Dose</arm_group_label>
    <arm_group_label>Male, Age 18 - 49, Half Dose</arm_group_label>
    <arm_group_label>Male, Age 18 -49, Full Dose</arm_group_label>
    <arm_group_label>Male, Age 50 -64, Full Dose</arm_group_label>
    <arm_group_label>Male, Age 50 -64, Half Dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Able to understand and comply with all study procedures including availability for all
             study visits and follow up surveys within 6 months following study enrollment.

          -  DEERS eligible beneficiaries eligible for influenza vaccination and able to give
             informed consent.

          -  Age 18-49

               -  Patients presenting to travel clinic with no exclusion criteria;

               -  Household contacts and out-of-home caretakers of infants from 6-23 months of age;

               -  Hospital and/or employees providing service to the public who are not eligible
                  for the post-October 5th recommendations for priority immunization;

               -  DOD employees eligible for influenza vaccination prior to October 5th but
                  excluded in the post October 5th guidelines;

               -  People living in dormitories or under other crowded conditions, to prevent
                  outbreaks;

          -  Ages 50-64 years of age who are not eligible for the post-October 5th recommendations
             for priority immunization and with no standard of care contraindications to
             vaccination.

          -  Eligible in the Department of Defense for influenza vaccination

        Exclusion Criteria:

          -  all children aged &lt; 18 years (includes children aged 6 months-18 years on chronic
             aspirin therapy);

          -  adults aged &gt;65 years;

          -  persons aged 2-64 years with underlying chronic medical conditions:

               -  includes persons with chronic cardiac or pulmonary disease, diabetes mellitus,
                  hemoglobinopathy, or immunosuppressive illness;

               -  any acute or chronic condition that, in the opinion of the investigator, would
                  render vaccination unsafe or interfere with the evaluation of response.

          -  use of experimental vaccines or medications within 30 days of study entry;

          -  receipt of parenteral immunoglobulin within 60 days of study entry;

          -  all women who will be pregnant during the influenza season;

          -  residents of nursing homes and long-term care facilities;

          -  health-care workers involved in direct patient care and included in DOD priority 1;
             and;

          -  military recruits;

          -  out-of-home caregivers and household contacts of children aged &lt;6 months.

          -  Anyone with clinical contraindications for receiving the inactivated influenza vaccine
             such as a history of severe allergic reaction to prior influenza vaccinations, severe
             allergy to egg and/or egg proteins and gelatin.

          -  DOD Priority 1: Deployed or deploying (with orders) service members and others
             designated as critical to national defense.

          -  DOD Priority 2: Medically high risk in accordance with ACIP guidelines (includes
             health-care workers with direct patient contact)

          -  Any acute or chronic condition that, in the opinion of the investigator or her
             provider designee would render vaccination unsafe or interfere with the evaluation of
             the response.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Renata J Engler, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Walter Reed Army Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pentagon</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20050</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Walter Reed Army Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20307</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Engler RJ, Nelson MR, Klote MM, VanRaden MJ, Huang CY, Cox NJ, Klimov A, Keitel WA, Nichol KL, Carr WW, Treanor JJ; Walter Reed Health Care System Influenza Vaccine Consortium. Half- vs full-dose trivalent inactivated influenza vaccine (2004-2005): age, dose, and sex effects on immune responses. Arch Intern Med. 2008 Dec 8;168(22):2405-14. doi: 10.1001/archinternmed.2008.513.</citation>
    <PMID>19064822</PMID>
  </results_reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>January 24, 2006</study_first_submitted>
  <study_first_submitted_qc>January 24, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2006</study_first_posted>
  <results_first_submitted>December 22, 2016</results_first_submitted>
  <results_first_submitted_qc>June 18, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">June 19, 2020</results_first_posted>
  <last_update_submitted>June 18, 2020</last_update_submitted>
  <last_update_submitted_qc>June 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study participants were recruited at the Walter Reed Army Medical Center Allergy-Immunization Clinic, the Fort Belvoir DeWitt Allergy-Immunization Clinic and the Pentagon Health Clinic during the annual influenza immunization program.</recruitment_details>
      <pre_assignment_details>Enrollment was expanded to include subs with a history of flu vacs. From the originally enrolled subjects (1316), the final data analysis includes only members of the baseline re-vaccination population (1114).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Full Dose, Age 18-49</title>
          <description>Subjects age 18-49 receiving full dose</description>
        </group>
        <group group_id="P2">
          <title>Half Dose, Age 18-49</title>
          <description>Subjects age 18-49 receiving half dose</description>
        </group>
        <group group_id="P3">
          <title>Full Dose, Age 50-64</title>
          <description>Subjects age 50-64 receiving full dose</description>
        </group>
        <group group_id="P4">
          <title>Half Dose, Age 50-64</title>
          <description>Subjects age 50-64 receiving half dose</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="274"/>
                <participants group_id="P2" count="284"/>
                <participants group_id="P3" count="280"/>
                <participants group_id="P4" count="276"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="274"/>
                <participants group_id="P2" count="284"/>
                <participants group_id="P3" count="280"/>
                <participants group_id="P4" count="276"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>FCSR didn't report baseline demographics per arm they were presented by age group.</population>
      <group_list>
        <group group_id="B1">
          <title>Full Dose, Age 18-49</title>
          <description>Previously Vaccinated Subjects Receiving Full Dose Aged 18-49 Years</description>
        </group>
        <group group_id="B2">
          <title>Half Dose, Age 18-49</title>
          <description>Previously Vaccinated Subjects Receiving Half Dose Aged 18-49 Years</description>
        </group>
        <group group_id="B3">
          <title>Full Dose, Age 50-64</title>
          <description>Previously Vaccinated Subjects Receiving Full Dose Aged 50-64 Years</description>
        </group>
        <group group_id="B4">
          <title>Half Dose, Age 50-64</title>
          <description>Previously Vaccinated Subjects Receiving Half Dose Aged 50-64 Years</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="274"/>
            <count group_id="B2" value="284"/>
            <count group_id="B3" value="280"/>
            <count group_id="B4" value="276"/>
            <count group_id="B5" value="1114"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="274"/>
                    <measurement group_id="B2" value="284"/>
                    <measurement group_id="B3" value="280"/>
                    <measurement group_id="B4" value="276"/>
                    <measurement group_id="B5" value="1114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="126"/>
                    <measurement group_id="B2" value="121"/>
                    <measurement group_id="B3" value="119"/>
                    <measurement group_id="B4" value="118"/>
                    <measurement group_id="B5" value="484"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="148"/>
                    <measurement group_id="B2" value="163"/>
                    <measurement group_id="B3" value="161"/>
                    <measurement group_id="B4" value="158"/>
                    <measurement group_id="B5" value="630"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="274"/>
                    <measurement group_id="B2" value="284"/>
                    <measurement group_id="B3" value="280"/>
                    <measurement group_id="B4" value="276"/>
                    <measurement group_id="B5" value="1114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Immune Response: Age 18-49</title>
        <description>Immune response as measured by viral strain specific hemaggluttination inhibition (HAI) antibody levels for subjects ages 18-49</description>
        <time_frame>21 days post-vaccincation</time_frame>
        <population>From the 1263 subjects enrolled, final analysis includes baseline re-vaccinated subs who fit all inc/exc criteria and whose serum specimens were usable. Data summarizes the differences in influenza strain specific serologic responses according to vaccine dose and age. Antibodies were measured by Hemagglutination Inhibition. GMT=Geometric Mean Titer</population>
        <group_list>
          <group group_id="O1">
            <title>Age 18 - 49, Full Dose</title>
            <description>0.5ml, 15µg Fluzone® (Aventis Pasteur inactivated influenza vaccine) hemagglutinin antigen per strain
Fluzone® (Aventis Pasteur inactivated influenza vaccine): A/H1N1, A/New Caledonia/20/99; A/H3N2, A/Fujian/411/2002; B, B/Shanghai/361/2002</description>
          </group>
          <group group_id="O2">
            <title>Age 18 - 49, Half Dose</title>
            <description>0.25ml, 7.5µg Fluzone® (Aventis Pasteur inactivated influenza vaccine) hemagglutinia per strain
Fluzone® (Aventis Pasteur inactivated influenza vaccine): A/H1N1, A/New Caledonia/20/99; A/H3N2, A/Fujian/411/2002; B, B/Shanghai/361/2002</description>
          </group>
        </group_list>
        <measure>
          <title>Immune Response: Age 18-49</title>
          <description>Immune response as measured by viral strain specific hemaggluttination inhibition (HAI) antibody levels for subjects ages 18-49</description>
          <population>From the 1263 subjects enrolled, final analysis includes baseline re-vaccinated subs who fit all inc/exc criteria and whose serum specimens were usable. Data summarizes the differences in influenza strain specific serologic responses according to vaccine dose and age. Antibodies were measured by Hemagglutination Inhibition. GMT=Geometric Mean Titer</population>
          <units>Anti-body response (GMT)</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="274"/>
                <count group_id="O2" value="284"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1 - GMT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.8" lower_limit="25.2" upper_limit="32.8"/>
                    <measurement group_id="O2" value="21.3" lower_limit="18.9" upper_limit="24.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 - GMT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.2" lower_limit="48.7" upper_limit="62.5"/>
                    <measurement group_id="O2" value="45.0" lower_limit="39.7" upper_limit="50.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B - GMT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.6" lower_limit="61.4" upper_limit="78.9"/>
                    <measurement group_id="O2" value="54.8" lower_limit="49.1" upper_limit="61.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Immune Response: Age 50-64</title>
        <description>Immune response as measured by viral strain specific hemaggluttination inhibition (HAI) antibody levels for subjects ages 50-64</description>
        <time_frame>21 days post-vaccincation</time_frame>
        <population>From the 1263 subjects enrolled, final analysis includes baseline re-vaccinated subs who fit all inc/exc criteria and whose serum specimens were usable. Data summarizes the differences in influenza strain specific serologic responses according to vaccine dose and age. Antibodies were measured by Hemagglutination Inhibition. GMT=Geometric Mean Titer</population>
        <group_list>
          <group group_id="O1">
            <title>Age 50 - 64, Full Dose</title>
            <description>0.5ml, 15µg Fluzone® (Aventis Pasteur inactivated influenza vaccine) hemagglutinin antigen per strain
Fluzone® (Aventis Pasteur inactivated influenza vaccine): A/H1N1, A/New Caledonia/20/99; A/H3N2, A/Fujian/411/2002; B, B/Shanghai/361/2002</description>
          </group>
          <group group_id="O2">
            <title>Age 50 - 64, Half Dose</title>
            <description>0.25ml, 7.5µg Fluzone® (Aventis Pasteur inactivated influenza vaccine) hemagglutinia per strain
Fluzone® (Aventis Pasteur inactivated influenza vaccine): A/H1N1, A/New Caledonia/20/99; A/H3N2, A/Fujian/411/2002; B, B/Shanghai/361/2002</description>
          </group>
        </group_list>
        <measure>
          <title>Immune Response: Age 50-64</title>
          <description>Immune response as measured by viral strain specific hemaggluttination inhibition (HAI) antibody levels for subjects ages 50-64</description>
          <population>From the 1263 subjects enrolled, final analysis includes baseline re-vaccinated subs who fit all inc/exc criteria and whose serum specimens were usable. Data summarizes the differences in influenza strain specific serologic responses according to vaccine dose and age. Antibodies were measured by Hemagglutination Inhibition. GMT=Geometric Mean Titer</population>
          <units>Anti-body response (GMT)</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="280"/>
                <count group_id="O2" value="276"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1 - GMT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.4" lower_limit="18.6" upper_limit="24.7"/>
                    <measurement group_id="O2" value="14.2" lower_limit="12.7" upper_limit="15.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 - GMT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.0" lower_limit="51.4" upper_limit="67.8"/>
                    <measurement group_id="O2" value="39.1" lower_limit="34.3" upper_limit="44.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B - GMT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.1" lower_limit="45.5" upper_limit="59.8"/>
                    <measurement group_id="O2" value="36.8" lower_limit="32.4" upper_limit="41.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Medical Events: Unsolicited Adverse Events</title>
        <description>Assessed through following subjects' recording of oral body temperature, completion of a 21-day symptom diary; subjects' completion of longer-term follow-up surveys to track respiratory symptoms; and a review of the Defense Medical Surveillance System (DMSS) hospitalization and outpatient medical visits database in order to track ICD-9 codes relevant to flu-like illness.</description>
        <time_frame>3 - 6 months following vaccination</time_frame>
        <population>Of the original population, 1203 previously vaccinated subjects completed the 3-day post vaccination side effects diary and have been included in the this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Mild</title>
            <description>Mild AE</description>
          </group>
          <group group_id="O2">
            <title>Moderate</title>
            <description>Moderate AE</description>
          </group>
          <group group_id="O3">
            <title>Severe, Able to Work</title>
            <description>Severe but able to work</description>
          </group>
          <group group_id="O4">
            <title>Severe, Lost Productivity</title>
            <description>Severe and lost productivity</description>
          </group>
          <group group_id="O5">
            <title>No Events</title>
            <description>No adverse events recorded</description>
          </group>
        </group_list>
        <measure>
          <title>Medical Events: Unsolicited Adverse Events</title>
          <description>Assessed through following subjects' recording of oral body temperature, completion of a 21-day symptom diary; subjects' completion of longer-term follow-up surveys to track respiratory symptoms; and a review of the Defense Medical Surveillance System (DMSS) hospitalization and outpatient medical visits database in order to track ICD-9 codes relevant to flu-like illness.</description>
          <population>Of the original population, 1203 previously vaccinated subjects completed the 3-day post vaccination side effects diary and have been included in the this analysis.</population>
          <units>Adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1203"/>
                <count group_id="O2" value="1203"/>
                <count group_id="O3" value="1203"/>
                <count group_id="O4" value="1203"/>
                <count group_id="O5" value="1203"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Body as a Whole</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="1193"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cardiovascular System</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1199"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Digestive Sytem</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="1182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematological and Lymphatic System</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Musculoskeletal System</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Respiratory System</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="1167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Skin and Appendages</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Special Senses</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urogenital System</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1199"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Symptions in Arm Given Shot</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1189"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1199"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Race/Ethnicity Baseline Measure</title>
        <description>Race/ethnicity data was only collected by age and cannot be separated out by dose as per the other Baseline Measures</description>
        <time_frame>Enrollment Day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aged 18-49 y (n=558)</title>
            <description>Race/Ethnicity stratified by age 18-49</description>
          </group>
          <group group_id="O2">
            <title>Aged 50-64 y (n=556)</title>
            <description>Race/Ethnicity stratified by age 50-64</description>
          </group>
        </group_list>
        <measure>
          <title>Race/Ethnicity Baseline Measure</title>
          <description>Race/ethnicity data was only collected by age and cannot be separated out by dose as per the other Baseline Measures</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="558"/>
                <count group_id="O2" value="556"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="454"/>
                    <measurement group_id="O2" value="491"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other/unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 - 6 months following vaccination</time_frame>
      <desc>Of the original study population, 1203 previously vaccinated subjects completed the 3-day post vaccination side effects diary and have been included in this analysis.
AEs were collected with diary cards, health surveys, and VAERS forms and listed by subject
Grading of AE's:
1 = Mild; 2 = Moderate; 3 = Severe, able to work; 4 = Severe, lost productivity; 5 = Life-threatening; 6 = Fatal</desc>
      <group_list>
        <group group_id="E1">
          <title>Full Dose</title>
          <description>0.5ml, 15µg Fluzone® (Aventis Pasteur inactivated influenza vaccine) hemagglutinin antigen per strain
Fluzone® (Aventis Pasteur inactivated influenza vaccine): A/H1N1, A/New Caledonia/20/99; A/H3N2, A/Fujian/411/2002; B, B/Shanghai/361/2002</description>
        </group>
        <group group_id="E2">
          <title>Half Dose</title>
          <description>0.25ml, 7.5µg Fluzone® (Aventis Pasteur inactivated influenza vaccine) hemagglutinia per strain
Fluzone® (Aventis Pasteur inactivated influenza vaccine): A/H1N1, A/New Caledonia/20/99; A/H3N2, A/Fujian/411/2002; B, B/Shanghai/361/2002</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="556"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid endarterectomey</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="556"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="556"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Melanoma exised</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="556"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="556"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Swollen lymph nodes</sub_title>
                <description>Grade 1</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Swollen lymph nodes in neck, sore throat, chills, body aches</sub_title>
                <description>Grade 1</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="556"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <description>Grade 1</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Irritable bowel syndrome</sub_title>
                <description>Grade 4</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Grade 1</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Nausea and body aches</sub_title>
                <description>Grade 4</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="556"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever, chills, flu-like symptoms</sub_title>
                <description>Grade 4</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Flu-like symptoms</sub_title>
                <description>Grade 4</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Flu-like symptoms</sub_title>
                <description>Grade 2</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="556"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Idiopathic urticaria</sub_title>
                <description>Grade 1</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="556"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Outbreak of HSV on face, also nasal lesions</sub_title>
                <description>Grade 2</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="556"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Brusing at injection site</sub_title>
                <description>Grade 1</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Bruising at injection site</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Aching at injection site</sub_title>
                <description>Grade 1</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Arm sore at injection site</sub_title>
                <description>Grade 1</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Hurt at injection site</sub_title>
                <description>Grade 2</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Ichiness at injection site</sub_title>
                <description>Grade 1</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Injection site soreness</sub_title>
                <description>Grade 1</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="554"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Itching, distil to injection site</sub_title>
                <description>Grade 1</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Pain in right antecubital area after venipuncture</sub_title>
                <description>Grade 1</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Tender at injection site</sub_title>
                <description>Grade 1</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Tingling in fingers of vaccinated arm</sub_title>
                <description>Grade 1</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Very sore at injection site</sub_title>
                <description>Grade 1</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="556"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Body aches</sub_title>
                <description>Grade 2</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Right shoulder pain</sub_title>
                <description>Grade 1</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Sore, achy shoulder</sub_title>
                <description>Grade 2</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="556"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash on right calf</sub_title>
                <description>Grade 2</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="556"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>COL Renata J. M. Engler, MD</name_or_title>
      <organization>Walter Reed National Vaccine Healthcare Center Network</organization>
      <phone>202-782-9461 ext 8819</phone>
      <email>renata.engler@na.amedd.army.mil</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

